Nahed A. Soliman
Research Subjects
Research Interests
Nahed A. Soliman has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Afaf Ibrahiem
Pathology departement faculty of medicine mansoura university
1 shared publication- Afaf Taha Ibrahiem
Department of Pathology, Faculty of Medicine, Northern Border University, Arar, Saudi Arabia
1 shared publication - Aly A. M. Shaalan
Department of Human Anatomy, Faculty of Medicine, Jazan University, Jazan 45142, Saudi Arabia
1 shared publication Azza Abdel-Aziz&Lrm
Pathology Departement, Mansoura Faculty of Medicine
1 shared publicationDoaa Ghorab
Pathology departement Mansoura faculty of Medicine
1 shared publication- Eman Ali Toraih
Faculty of Medicine, Suez Canal University, Ismailia, Egypt
1 shared publication
Latest Publications
- Open Access
- 1 November 2023
- Published by Egyptian Knowledge Bank in Benha Medical Journal
- Vol. 40 (Special (A) , 107-124
Inverse correlation of concurrent BCL2, and C MYC expressions and CD30 positivity as regard the Prognostic significance in diffuse large B-cell lymphoma
Background : C MYC, BCL2 and CD30 play an important role in initiation and propagation of diffuse large B-cell lymphoma (DLBCL). Protein expression of these marker were used in the diagnosis, predicting the prognosis and as a therapeutic target in DLBCLpurpose: this study aimed to assess the prognostic impact and therapeutic utility of expression patterns of CD30, BCL2, MYC in DLBCLPatients and Methods: This retrospective study was carried out on DLBCL diagnosed at Oncology Centre Mansoura University (2016-2019). The study was approved by IRB of Mansoura faculty of Medicine Code Number: R.23.01.2043, 21/03/2023.Results: BCL2, C MYC, concurrent BCL2,C MYC and CD30 overexpression was present in 76%, 36%,, 26% and 26% of the studied cases respectively. Concurrent expressions of BCL2, C MYC showed significant association with the presence relapse (P= 0.003). concurrent expression of BCL2, C MYC revealed significant association with the progressive therapy response (P=0.003). In addition, C MYC, expression was significantly associated with the presence of exranodal presentation (P=0.03). CD30 protein overexpression was significantly associated with stage II and III (P=0.03). CD30 positivity showed inverse correlation with the concurrent expression of BCL2, C MYC (Correlation Coefficient=--.355, P=0,02). Also CD30 positivity and concurrent expression of BCL2, C MYC reflected significant prognostic impact on overall survival (OS) and disease free survival (DFS) (all P=0.00).Conclusion: concurrent C MYC, BCL2 overexpression is associated with a lower OS, and DFS. CD30 positivity is associated with a better OS, and DFS which can be utilized in management plan of DLBCL.
- 1 November 2023
- Published by Egyptian Knowledge Bank in Benha Medical Journal
- Vol. 40 (Special (A) , 107-124
Open AccessInverse correlation of concurrent BCL2, and C MYC expressions and CD30 positivity as regard the Prognostic significance in diffuse large B-cell lymphoma
Background : C MYC, BCL2 and CD30 play an important role in initiation and propagation of diffuse large B-cell lymphoma (DLBCL). Protein expression of these marker were used in the diagnosis, predicting the prognosis and as a therapeutic target in DLBCLpurpose: this study aimed to assess the prognostic impact and therapeutic utility of expression patterns of CD30, BCL2, MYC in DLBCLPatients and Methods: This retrospective study was carried out on DLBCL diagnosed at Oncology Centre Mansoura University (2016-2019). The study was approved by IRB of Mansoura faculty of Medicine Code Number: R.23.01.2043, 21/03/2023.Results: BCL2, C MYC, concurrent BCL2,C MYC and CD30 overexpression was present in 76%, 36%,, 26% and 26% of the studied cases respectively. Concurrent expressions of BCL2, C MYC showed significant association with the presence relapse (P= 0.003). concurrent expression of BCL2, C MYC revealed significant association with the progressive therapy response (P=0.003). In addition, C MYC, expression was significantly associated with the presence of exranodal presentation (P=0.03). CD30 protein overexpression was significantly associated with stage II and III (P=0.03). CD30 positivity showed inverse correlation with the concurrent expression of BCL2, C MYC (Correlation Coefficient=--.355, P=0,02). Also CD30 positivity and concurrent expression of BCL2, C MYC reflected significant prognostic impact on overall survival (OS) and disease free survival (DFS) (all P=0.00).Conclusion: concurrent C MYC, BCL2 overexpression is associated with a lower OS, and DFS. CD30 positivity is associated with a better OS, and DFS which can be utilized in management plan of DLBCL.
- Open Access
- 9 January 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (2) , 237
Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma
Patients with colorectal cancer in different stages show variable outcomes/therapeutic responses due to their distinct tumoral biomarkers and biological features. In this sense, this study aimed to explore the prognostic utility of BRAF, programmed death-1 (PD1), and its ligand (PDL1) protein signatures in colon adenocarcinoma. The selected protein markers were explored in 64 archived primary colon adenocarcinomas in relation to clinicopathological features. BRAF overexpression was found in 39% of the cases and was significantly associated with grade 3, N1, advanced Dukes stage, presence of relapse, and shorter overall survival (OS). PD1 expression in the infiltrating immune cells (IICs) exhibited significant association with T2/T3, N0/M0, early Dukes stage, and absence of relapse. PDL1 expression in IICs is significantly associated with advanced nodal stage/distant metastasis, advanced Dukes stage, and shorter OS. Meanwhile, PDL1 expression in neoplastic cells (NC) was associated with the advanced lymph node/Dukes stage. A positive combined expression pattern of PDL1 in NC/IICs was associated with poor prognostic indices. Tumor PDL1 expression can be an independent predictor of OS and DFS. The multivariate analyses revealed that short OS was independently associated with the RT side location of the tumor, PD1 expression in stromal IICs, and PDL1 expression in NC. In conclusion, overexpression of BRAF in colon adenocarcinoma is considered a poor prognostic pathological marker. In addition, PDL1 expression in NC is considered an independent prognostic factor for DFS/OS. Combined immunohistochemical assessment for BRAF and PD1/PDL1 protein expressions in colon adenocarcinoma might be beneficial for selecting patients for future targeted therapy.
- 9 January 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (2) , 237
Open AccessPrognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma
Patients with colorectal cancer in different stages show variable outcomes/therapeutic responses due to their distinct tumoral biomarkers and biological features. In this sense, this study aimed to explore the prognostic utility of BRAF, programmed death-1 (PD1), and its ligand (PDL1) protein signatures in colon adenocarcinoma. The selected protein markers were explored in 64 archived primary colon adenocarcinomas in relation to clinicopathological features. BRAF overexpression was found in 39% of the cases and was significantly associated with grade 3, N1, advanced Dukes stage, presence of relapse, and shorter overall survival (OS). PD1 expression in the infiltrating immune cells (IICs) exhibited significant association with T2/T3, N0/M0, early Dukes stage, and absence of relapse. PDL1 expression in IICs is significantly associated with advanced nodal stage/distant metastasis, advanced Dukes stage, and shorter OS. Meanwhile, PDL1 expression in neoplastic cells (NC) was associated with the advanced lymph node/Dukes stage. A positive combined expression pattern of PDL1 in NC/IICs was associated with poor prognostic indices. Tumor PDL1 expression can be an independent predictor of OS and DFS. The multivariate analyses revealed that short OS was independently associated with the RT side location of the tumor, PD1 expression in stromal IICs, and PDL1 expression in NC. In conclusion, overexpression of BRAF in colon adenocarcinoma is considered a poor prognostic pathological marker. In addition, PDL1 expression in NC is considered an independent prognostic factor for DFS/OS. Combined immunohistochemical assessment for BRAF and PD1/PDL1 protein expressions in colon adenocarcinoma might be beneficial for selecting patients for future targeted therapy.